Alendronate for the prevention of bone loss in patients on inhaled steroid therapy
Publication in refereed journal

Times Cited
Web of Science15WOS source URL (as at 13/09/2021) Click here for the latest count
Altmetrics Information

Other information
AbstractOne hundred women on inhaled steroid therapy (dose range from 800 to < 1600 mug per day) were randomized to receive 10 mg of oral alendronate or placebo (with 500 mg of calcium in the form of daily calcium carbonate). Bone mineral density (BMD) was measured at baseline, 6 months, and 12 months. The percentage changes in BMD were - 0.80 % in the placebo group and 2.99 % in the alendronate group at the spine (p < 0.001 by analysis of covariance [ANCOVA]), and were -0.51 % in the placebo group and 0.97 % in the alendronate group at the femoral neck (p < 0.05 by ANCOVA). Five patients in the alendronate-treated group, and a similar number of patients in the placebo group, complained of mild gastric discomfort. We conclude that women on inhaled steroid therapy were at risk of accelerated bone loss, which could be prevented by a daily dose of 10 mg of alendronate. (C) 2001 by Elsevier Science Inc. All rights reserved.
All Author(s) ListLau EMC, Woo J, Chan YH, Li M
Journal nameBONE
Volume Number29
Issue Number6
Pages506 - 510
LanguagesEnglish-United Kingdom
Keywordsalendronate; bisphosphonates; inhaled steroids; osteoporosis
Web of Science Subject CategoriesEndocrinology & Metabolism; ENDOCRINOLOGY & METABOLISM

Last updated on 2021-14-09 at 00:37